Kyntra Bio (KYNB) Stock Price, News & Analysis

Company Overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $6.82 to $7.05
• 50-Day Range: $6.46 to $7.37
• 52-Week Range: $4.85 to $12.60
• Volume: 11,629 shs
• Average Volume: 7,911 shs
• Market Capitalization: $28.31 million
• P/E Ratio: 0.17
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Kyntra Bio Stock Analysis - MarketRank™

Kyntra Bio scored higher than 20% of companies evaluated by MarketBeat, and ranked 66th out of 81 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Kyntra Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Kyntra Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kyntra Bio are expected to grow in the coming year, from ($13.89) to ($9.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyntra Bio is 0.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.96.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyntra Bio is 0.17, which means that it is trading at a less expensive P/E ratio than the Manufacturing sector average P/E ratio of about 21.96.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.86% of the float of Kyntra Bio has been sold short.

Short Interest Ratio / Days to Cover

Kyntra Bio has a short interest ratio ("days to cover") of 17.67, which indicates bearish sentiment.

Change versus previous month

Short interest in Kyntra Bio has recently increased by 0.49%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kyntra Bio does not currently pay a dividend.

Dividend Growth

Kyntra Bio does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyntra Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.98% of the stock of Kyntra Bio is held by insiders.

Percentage Held by Institutions

72.71% of the stock of Kyntra Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 5/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KYNB
• CIK: 921299
• Web: N/A
• Phone: (415) 978-1200
• Fax: 415-978-1902
• Employees: 570
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $40.46
• Trailing P/E Ratio: 0.17
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $183.45 million
• Net Margins: 2,199.13%
• Pretax Margin: -761.59%
• Return on Equity: N/A
• Return on Assets: -36.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.61
• Quick Ratio: 3.48

Sales & Book Value

• Annual Sales: $6.44 million
• Price / Sales: 4.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($7.60) per share
• Price / Book: -0.92

Miscellaneous

• Outstanding Shares: 4,050,000
• Free Float: 3,968,000
• Market Cap: $28.31 million
• Optionable: N/A
• Beta: 1.03